Evidence map›Paper›PMID 35163565›Full record

ArticleInternational journal of molecular sciences2022

Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors.

Shivanand Pudakalakatti, Mark Titus, José S Enriquez, Sumankalai Ramachandran, Niki M Zacharias, Imad Shureiqi, Yi Liu, James C Yao, Xiangsheng Zuo, Pratip K Bhattacharya

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. NMR-based metabolomics: Where are we now and where are we going?Progress in nuclear magnetic resonance spectroscopy
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shivanand PudakalakattiDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mark TitusDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
José S EnriquezDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Sumankalai RamachandranDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Niki M ZachariasMD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Imad ShureiqiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-2019-938X
Yi LiuDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
James C YaoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiangsheng ZuoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pratip K BhattacharyaDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-0625-252X
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI James Versalovic · 2001 to 2026
$28.3M
TASK ORDER TITLE: EVALUATION OF REAL-TIME METABOLIC IMAGING BIOMARKERS FOR DETECTION OF PANCREATIC PREMALIGNANT LESIONS75N91019D00021 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIANGWEI · 2019 to 2025
$13.7M
Circulating Biomarkers and Imaging for Early Detection of Pancreatic CancerU01CA214263 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EUGENE J KOAY, Subrata Sen · 2018 to 2026
$7.2M
Molecular Understanding and Targeting of Determinant Factors in Gastric TumorigenesisR01CA236905 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZUO, XIANGSHENG · 2021 to 2025
$1.8M
Targeted Hyperpolarized Molecular Beacons for Colorectal Cancer DetectionR21EB031217 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHATTACHARYA, PRATIP K. · 2021 to 2023
$648k
ω-3 fatty acid-derived mediators promote resolution of inflammation: Uncovering new strategies for preventing colitis-associated colon cancerR03CA235106 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZUO, XIANGSHENG · 2020 to 2021
$160k
Cancer Prevention and Research Institute of Texas RP180164NCI NIH HHS 75N91019D00021NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA236905NCI NIH HHS R01CA236905 and R03CA235106NCI NIH HHS R03 CA235106NCI NIH HHS U01 CA214263 and R21 CA185536NIBIB NIH HHS R21 EB031217NIDDK NIH HHS P30 DK056338
6 · The paper itself

Abstract

Peroxisome proliferator-activated receptor delta (PPARD) is a nuclear receptor known to play an essential role in regulation of cell metabolism, cell proliferation, inflammation, and tumorigenesis in normal and cancer cells. Recently, we found that a newly generated villin-PPARD mouse model, in which PPARD is overexpressed in villin-positive gastric progenitor cells, demonstrated spontaneous development of large, invasive gastric tumors as the mice aged. However, the role of PPARD in regulation of downstream metabolism in normal gastric and tumor cells is elusive. The aim of the present study was to find PPARD-regulated downstream metabolic changes and to determine the potential significance of those changes to gastric tumorigenesis in mice. Hyperpolarized [1-13C] pyruvate magnetic resonance spectroscopy, nuclear magnetic resonance spectroscopy, and liquid chromatography-mass spectrometry were employed for metabolic profiling to determine the PPARD-regulated metabolite changes in PPARD mice at different ages during the development of gastric cancer, and the changes were compared to corresponding wild-type mice. Nuclear magnetic resonance spectroscopy-based metabolomic screening results showed higher levels of inosine monophosphate (p = 0.0054), uracil (p = 0.0205), phenylalanine (p = 0.017), glycine (p = 0.014), and isocitrate (p = 0.029) and lower levels of inosine (p = 0.0188) in 55-week-old PPARD mice than in 55-week-old wild-type mice. As the PPARD mice aged from 10 weeks to 35 weeks and 55 weeks, we observed significant changes in levels of the metabolites inosine monophosphate (p = 0.0054), adenosine monophosphate (p = 0.009), UDP-glucose (p = 0.0006), and oxypurinol (p = 0.039). Hyperpolarized [1-13C] pyruvate magnetic resonance spectroscopy performed to measure lactate flux in live 10-week-old PPARD mice with no gastric tumors and 35-week-old PPARD mice with gastric tumors did not reveal a significant difference in the ratio of lactate to total pyruvate plus lactate, indicating that this PPARD-induced spontaneous gastric tumor development does not require glycolysis as the main source of fuel for tumorigenesis. Liquid chromatography-mass spectrometry-based measurement of fatty acid levels showed lower linoleic acid, palmitic acid, oleic acid, and steric acid levels in 55-week-old PPARD mice than in 10-week-old PPARD mice, supporting fatty acid oxidation as a bioenergy source for PPARD-expressing gastric tumors.

Indexed as

Up-RegulationAdenosine MonophosphateAnimalsChromatography, LiquidFatty AcidsFemaleGenetic EngineeringMagnetic Resonance ImagingMaleMass SpectrometryMetabolomicsMiceMicrofilament ProteinsNeoplasms, ExperimentalOxypurinolPPAR deltaAdenosine MonophosphateFatty AcidsMicrofilament ProteinsOxypurinolPPAR deltaUridine Diphosphate GlucoseVil1 protein, mousegastric cancerhyperpolarized [1-13C] pyruvate MR spectroscopyLC-MSmetabolic imagingmetabolitesmetabolomicsNMR spectroscopyPPARD

Identifiers

PMID35163565
PMCPMC8835946
OpenAlexW4210724552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.